Home » Clinical Trials » Location » Japan
One Or Multiple Investigational Sites, Japan Clinical Trials
A listing of One Or Multiple Investigational Sites, Japan clinical trials actively recruiting patients volunteers.
Found (7076) clinical trials
NASH001 - Non-alcoholic Steatohepatitis (NASH) - CC-90001-NASH-001 - US
Primary Outcome Measures :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis [ Time Frame: Up to approximately 52 weeks ]Assessment of liver fibrosis score by the NASH Clinical Research Network (CRN) scoring systemSecondary Outcome Measures :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis and no worsening of steatohepatitis ...
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US
This is a single-arm, multi-cohort, multi-center, Phase 2 study to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell NHL. The study will enroll subjects in Europe and Japan with DLBCL NOS (de novo or tFL), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ...
A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Primary Objective: To compare the pharmacokinetics (PK) of single and multiple doses of IPX203 with Immediate release carbidopa-levodopa (IR CD-LD) in subjects with advanced Parkinson's disease (PD). Secondary Objectives: To compare the pharmacodynamics of single and multiple doses of IPX203 with IR CD-LD. To compare the efficacy of IPX203 with ...
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of PD patients who continue to have dyskinesia on amantadine.
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Moderate-to-Severe Chronic Plaque-Type Psoriasis
The study will include a 4 week screening and washout phase, a 12 week treatment phase and a 4 week observational post treatment followup phase to evaluate safety and disease relapse and rebound. This is an oral medication.
A phase 2A, randomized, double-blind, placebo-controoled, study to evaluate safety and efficacy of PF-06700841 in subjects with moderate to severe plaque psoriasis.
12 week double-blind study with a 8 week followup.
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases
Volunteers with neutrophilic skin disease are needed to participate in a research study to assess the safety, tolerability, and activity of an investigational drug that is being developed as a potential treatment for plaque psoriasis, palmoplantar pustulosis, or hidradenitis suppurativa. Eligible participants will be men and women diagnosed with one ...
A randomized, double-blind, placebo-controoled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis.
52 week study. Cosentyx vs placebo for 12 weeks, open label week 12-52.
Atopic Dermatitis (Eczema)
A study of the saftey, effectiveness and tolerability of an investigational treatment for individuals with atopic dermatitis. REF: x40-CLN
